Bayer starts Phase II in sleep disturbances associated with menopause

 

• New Phase II study NIRVANA aims to explore efficacy and safety of investigational compound elinzanetant as a non-hormonal treatment for sleep disturbances associated with menopause (SDM)
• SDM may have an impact on women’s quality of life, work productivity as well as their physical and mental wellbeing
• The new Phase II study expands upon the ongoing clinical development program of elinzanetant, an investigational first dual neurokinin-1,3 (NK-1, 3) receptor antagonist

https://www.biospace.com/article/releases/bayer-starts-phase-ii-study-nirvana-to-evaluate-elinzanetant-in-women-with-sleep-disturbances-associated-with-menopause/